{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T08:10:04Z","timestamp":1747901404988,"version":"3.41.0"},"reference-count":29,"publisher":"Danish Medical Association","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ugeskr L\u00e6ger"],"abstract":"<jats:p>Psoriasis is a common chronic inflammatory skin disease with several clinical subtypes. Recent discoveries in the genetics and immunology of the disease, particularly in plaque psoriasis, have revolutionised the treatment of patients with psoriasis. An understanding of the differences in genetics and immunology between different psoriasis subtypes is emerging. This review finds that the unraveling of the links between clinical presentation, genetics, immunology, treatment response, and comorbidities will allow for more individualised treatment of patients with psoriasis in the future.<\/jats:p>","DOI":"10.61409\/v06240401","type":"journal-article","created":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T13:24:17Z","timestamp":1731331457000},"page":"1-9","source":"Crossref","is-referenced-by-count":0,"title":["Psoriasis is a disease with several clinical presentations"],"prefix":"10.61409","author":[{"given":"Amanda","family":"Kvist-Hansen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"N\u00e4slund-Koch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lone","family":"Skov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"40208","published-online":{"date-parts":[[2024,11,11]]},"reference":[{"key":"ref0","unstructured":"World Health Organization. Global report on psoriasis, 2016. https:\/\/www.who.int\/publications\/i\/item\/9789241565189 (5. jun 2024)"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Glickman FS. Lepra, psora, psoriasis. J Am Acad Dermatol. 1986;14(5 Pt 1):863-6. https:\/\/doi.org\/10.1016\/s0190-9622(86)70101-1","DOI":"10.1016\/S0190-9622(86)70101-1"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Pearl RL, Wan MT, Takeshita J, Gelfand JM. Stigmatizing attitudes toward persons with psoriasis among laypersons and medical students. J Am Acad Dermatol. 2019;80(6):1556-1563. https:\/\/doi.org\/10.1016\/j.jaad.2018.08.014","DOI":"10.1016\/j.jaad.2018.08.014"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Rasmussen MK, Enger M, Dahlborn AK et al. The importance of achieving clear or almost clear skin for patients: results from the Nordic countries of the global. Acta Derm Venereol. 2019;99(2):158-163. https:\/\/doi.org\/10.2340\/00015555-3048","DOI":"10.2340\/00015555-3048"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Rapp SR, Feldman SR, Exum ML et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3 Pt 1):401-7. https:\/\/doi.org\/10.1016\/s0190-9622(99)70112-x","DOI":"10.1016\/S0190-9622(99)70112-X"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Randa H, Todberg T, Skov L et al. Health-related quality of life in children and adolescents with psoriasis: a systematic review and meta-analysis. Acta Derm Venereol. 2017;97(5):555-563. https:\/\/doi.org\/10.2340\/00015555-2600","DOI":"10.2340\/00015555-2600"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10251):1301-1315. https:\/\/doi.org\/10.1016\/S0140-6736(20)32549-6","DOI":"10.1016\/S0140-6736(20)32549-6"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945-1960. https:\/\/doi.org\/10.1001\/jama.2020.4006","DOI":"10.1001\/jama.2020.4006"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol. 1985;13(3):450-6. https:\/\/doi.org\/10.1016\/s0190-9622(85)70188-0","DOI":"10.1016\/S0190-9622(85)70188-0"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Bachelez H, Barker J, Burden AD et al. Generalized pustular psoriasis is a disease distinct from psoriasis vulgaris: evidence and expert opinion. Expert Rev Clin Immunol. 2022;18(10):1033-1047. https:\/\/doi.org\/10.1080\/1744666X.2022.2116003","DOI":"10.1080\/1744666X.2022.2116003"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Twelves S, Mostafa A, Dand N et al. Clinical and genetic differences between pustular psoriasis subtypes. J Allergy Clin Immunol. 2019;143(3):1021-1026. https:\/\/doi.org\/10.1016\/j.jaci.2018.06.038","DOI":"10.1016\/j.jaci.2018.06.038"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Alinaghi F, Calov M, Kristensen LE et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251-265.e19. https:\/\/doi.org\/10.1016\/j.jaad.2018.06.027","DOI":"10.1016\/j.jaad.2018.06.027"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957-970. https:\/\/doi.org\/10.1056\/NEJMra1505557","DOI":"10.1056\/NEJMra1505557"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Dand N, Stuart PE, Bowes J et al. GWAS meta-analysis of psoriasis identifies new susceptibility alleles impacting disease mechanisms and therapeutic targets. medRxiv. 2023:2023.10.04.23296543. https:\/\/doi.org\/10.1101\/2023.10.04.23296543 (preprint).","DOI":"10.1101\/2023.10.04.23296543"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Dand N, Mahil SK, Capon F et al. Psoriasis and genetics. Acta Derm Venereol. 2020;100(3):adv00030. https:\/\/doi.org\/10.2340\/00015555-3384","DOI":"10.2340\/00015555-3384"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Enerb\u00e4ck C, Martinsson T, Inerot A et al. Significantly earlier age at onset for the HLA-Cw6-positive than for the Cw6-negative psoriatic sibling. J Invest Dermatol. 1997;109(5):695-6. https:\/\/doi.org\/10.1111\/1523-1747.ep12338329","DOI":"10.1111\/1523-1747.ep12338329"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Van Vugt LJ, van Den Reek JMPA, Hannink G et al. Association of HLA-C*06:02 status with differential response to ustekinumab in patients with psoriasis: a systematic review and meta-analysis. JAMA Dermatol. 2019;155(6):708-715. https:\/\/doi.org\/10.1001\/jamadermatol.2019.0098","DOI":"10.1001\/jamadermatol.2019.0098"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Siewertsen M, Al-Sofi R, Dridi H et al. Association between HLA-Cw6 and response to treatment with biologics in patients with psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2023;37(5):e611-e614. https:\/\/doi.org\/10.1111\/jdv.18870","DOI":"10.1111\/jdv.18870"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Monreal MTM, Kvist-Hansen A, Massarenti L et al. Characterization of circulating extracellular traps and immune responses to citrullinated LL37 in psoriasis. Front Immunol. 2023;14:1247592. https:\/\/doi.org\/10.3389\/fimmu.2023.1247592","DOI":"10.3389\/fimmu.2023.1247592"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Thein D, Egeberg A, Skov L, Loft N. Absolute and relative risk of new-onset psoriasis associated with tumor necrosis factor-\u03b1 inhibitor treatment in patients with immune-mediated inflammatory diseases: a Danish nationwide cohort study. JAMA Dermatol. 2022;158(9):997-1004. https:\/\/doi.org\/10.1001\/jamadermatol.2022.2360","DOI":"10.1001\/jamadermatol.2022.2360"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Maronese CA, Costanzo A, Gilliet M, Marzano AV. Paradoxical psoriasis: from its many faces to possible shared therapeutic targets. J Invest Dermatol. 2024;144(9):2084-2085. https:\/\/doi.org\/10.1016\/j.jid.2024.03.007","DOI":"10.1016\/j.jid.2024.03.007"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Morita A, Strober B, Burden AD et al. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial. Lancet. 2023;402(10412):1541-1551. https:\/\/doi.org\/10.1016\/S0140-6736(23)01378-8","DOI":"10.1016\/S0140-6736(23)01378-8"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Burden AD, Bissonnette R, Navarini AA et al. Spesolimab efficacy and safety in patients with moderate-to-severe palmoplantar pustulosis: a multicentre, double-blind, randomised, placebo-controlled, phase IIb, dose-finding study. Dermatol Ther (Heidelb). 2023;13(10):2279-2297. https:\/\/doi.org\/10.1007\/s13555-023-01002-1","DOI":"10.1007\/s13555-023-01002-1"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Takeshita J, Grewal S, Langan SM et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76(3):377-390. https:\/\/doi.org\/10.1016\/j.jaad.2016.07.064","DOI":"10.1016\/j.jaad.2016.07.064"},{"key":"ref24","unstructured":"Kvist-Hansen A, Kaiser H, Skov L, Hansen PR. Psoriasiskomorbiditet er mere end psoriasisartritis. Ugeskr L\u00e6ger. 2018;180:V07170526"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Niknezhad N, Haghighatkhah HR, Zargari O et al. High-sensitivity C-reactive protein as a biomarker in detecting subclinical atherosclerosis in psoriasis. Dermatol Ther. 2020;33(4):e13628. https:\/\/doi.org\/10.1111\/dth.13628","DOI":"10.1111\/dth.13628"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 2005;2005(5):273-9. https:\/\/doi.org\/10.1155\/MI.2005.273","DOI":"10.1155\/MI.2005.273"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Andersen CSB, Kvist-Hansen A, Siewertsen M et al. Blood cell biomarkers of inflammation and cytokine levels as predictors of response to biologics in patients with psoriasis. Int J Mol Sci. 2023;24(7):6111. https:\/\/doi.org\/10.3390\/ijms24076111","DOI":"10.3390\/ijms24076111"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Douroudis K, Ramessur R, Barbosa IA et al. Differences in clinical features and comorbid burden between HLA-C\u221706:02 carrier groups in >9,000 people with psoriasis. J Invest Dermatol. 2022;142(6):1617-1628.e10. https:\/\/doi.org\/10.1016\/j.jid.2021.08.446","DOI":"10.1016\/j.jid.2021.08.446"}],"container-title":["Ugeskrift for L\u00e6ger"],"original-title":[],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T07:31:43Z","timestamp":1747899103000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/videnskab\/V06240401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,11]]},"references-count":29,"URL":"https:\/\/doi.org\/10.61409\/v06240401","relation":{},"ISSN":["0041-5782","1603-6824"],"issn-type":[{"type":"print","value":"0041-5782"},{"type":"electronic","value":"1603-6824"}],"subject":[],"published":{"date-parts":[[2024,11,11]]}}}